Patents by Inventor Uwe Jacob
Uwe Jacob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945863Abstract: The present invention relates to a nucleic acid molecule encoding a chain myeloid capable of specifically binding to CD33, CD16 and CD123, wherein said nucleic molecule comprises: (a) a nucleic add molecule encoding a protein represented by SEQ ID NO:1; (b) a nucleic acid molecule represented by SEQ ID NO:2; (c) the nucleic add molecule of (b), wherein each thymine is replaced by urea; (d) a nucleic acid molecule encoding a protein having at least 98% sequence identity to the protein of (a); or (e) a nucleic add molecule that is degenerate with respect to the nucleic acid molecule of (b) or (c). The present invention further relates to a vector comprising the nucleic acid molecule of the invention, a host cell transformed or transfected with the nucleic acid molecule or the vector of the invention, as well as to a method for the production of a single chain myeloid capable of specifically binding to CD33, CD16 and CD123.Type: GrantFiled: December 1, 2017Date of Patent: April 2, 2024Assignee: Friedrich-Alexander-Universität Erlangen-NürnbergInventors: Georg H. Fey, Todd Braciak, Claudia C. Roskopf, Ingo Schubert, Karl-Peter Hopfner, Nadja Fenn, Sarah Wildenhain, Uwe Jacob
-
Publication number: 20240085575Abstract: A phase-contrast imaging detector includes a plurality of pixels. Each pixel includes a detection material that generates a measurable parameter in response to X-ray photons. Each pixel also includes a plurality of sub-pixel resolution readout structures. The sub-pixel resolution readout structures are in an alternating pattern with a spacing therebetween that is larger than a frequency of a phase-contrast interference pattern but small enough to enable charge sharing between adjacent sub-pixel resolution readout structures when an X-ray photon hits between the adjacent sub-pixel resolution readout structures. The phase-contrast imaging detector also includes readout circuitry configured to read out signals from the plurality of sub-pixel readout structures. The plurality of sub-pixel resolution readout structures includes two or more electrodes having alternating arms that form an interleaved comb structure.Type: ApplicationFiled: November 21, 2023Publication date: March 14, 2024Inventors: Uwe Wiedmann, Biju Jacob, Brian David Yanoff
-
Patent number: 10669324Abstract: The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same.Type: GrantFiled: October 30, 2013Date of Patent: June 2, 2020Assignee: SUPPREMOL GMBHInventors: Peter Sondermann, Dominik Ter Meer, Thomas Pohl, Reno Winter, Uwe Jacob
-
Publication number: 20190359710Abstract: The present invention relates to a nucleic acid molecule encoding a chain myeloid capable of specifically binding to CD33, CD16 and CD123, wherein said nucleic molecule comprises: (a) a nucleic add molecule encoding a protein represented by SEQ ID NO:1; (b) a nucleic acid molecule represented by SEQ ID NO:2; (c) the nucleic add molecule of (b), wherein each thymine is replaced by urea; (d) a nucleic acid molecule encoding a protein having at least 98% sequence identity to the protein of (a); or (e) a nucleic add molecule that is degenerate with respect to the nucleic acid molecule of (b) or (c). The present invention further relates to a vector comprising the nucleic acid molecule of the invention, a host cell transformed or transfected with the nucleic acid molecule or the vector of the invention, as well as to a method for the production of a single chain myeloid capable of specifically binding to CD33, CD16 and CD123.Type: ApplicationFiled: December 1, 2017Publication date: November 28, 2019Inventors: Georg H. Fey, Todd Braciak, Claidia C. Roskopf, Ingo Schubert, Karl-Peter Hopfner, Nadja Fenn, Sarah Wildenhein, Uwe Jacob
-
Publication number: 20150274804Abstract: The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same.Type: ApplicationFiled: October 30, 2013Publication date: October 1, 2015Inventors: Peter Sondermann, Dominik Ter Meer, Thomas Pohl, Reno Winter, Uwe Jacob
-
Patent number: 8853363Abstract: The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc?RIIb or Fc?RIIa.Type: GrantFiled: November 26, 2004Date of Patent: October 7, 2014Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Robert Huber, Peter Sondermann, Uwe Jacob, Kerstin Wendt, Chiara Cabrele, Luis Moroder
-
Patent number: 8666680Abstract: Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycoslyation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host ells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modeling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that an be used to separate and/or enrich antibodies.Type: GrantFiled: October 13, 2011Date of Patent: March 4, 2014Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter Sondermann, Robert Huber, Uwe Jacob
-
Publication number: 20130303458Abstract: The invention relates to the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis.Type: ApplicationFiled: June 7, 2013Publication date: November 14, 2013Inventors: Peter BUCKEL, Uwe JACOB
-
Publication number: 20120269837Abstract: This invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc?RIIb and Fc?RIIa.Type: ApplicationFiled: June 8, 2012Publication date: October 25, 2012Inventors: Robert Huber, Peter Sondermann, Uwe Jacob, Kerstin Wendt, Chiara Cabrele, Luis Moroder
-
Publication number: 20120190821Abstract: Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycoslyation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host ells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modeling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that an be used to separate and/or enrich antibodies.Type: ApplicationFiled: October 13, 2011Publication date: July 26, 2012Inventors: Peter SONDERMANN, Robert HUBER, Uwe JACOB
-
Publication number: 20110230391Abstract: The invention relates to the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fc? receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis.Type: ApplicationFiled: September 2, 2009Publication date: September 22, 2011Inventors: Peter Buckel, Uwe Jacob
-
Publication number: 20100240076Abstract: A method for a quantitative in vitro analysis to diagnose, to categorise, to predict and/or to monitor the progression of a condition comprising the following steps: a) Obtaining a sample suspected of containing anti-A-antibodies from a subject to be analysed, b) Providing native and mutant antigen A, c) Contacting the sample suspected of containing anti-A-antibodies with mutant antigen A and with native antigen A, d) Detecting the amount of anti-A-antibodies bound to native antigen A after step c), wherein the presence of anti-A-antibodies bound to native antigen A allows the diagnosis, the categorisation, the prediction and/or the monitoring of the progression of a condition.Type: ApplicationFiled: July 12, 2007Publication date: September 23, 2010Inventors: Uwe Jacob, Constanze Breithaupt, Robert Huber
-
Publication number: 20090292113Abstract: Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modelling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that can be used to separate and/or enrich antibodies.Type: ApplicationFiled: March 16, 2009Publication date: November 26, 2009Inventors: Peter Sondermann, Robert Huber, Uwe Jacob
-
Patent number: 7504482Abstract: Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modelling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that can be used to separate and/or enrich antibodies.Type: GrantFiled: January 6, 2006Date of Patent: March 17, 2009Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Peter Sondermann, Robert Huber, Uwe Jacob
-
Publication number: 20080214459Abstract: The present invention concerns pharmaceutical compositions containing one of the receptors Fc?R IIa, Fc?R IIb or Fc?R III in a recombinantly produced, soluble form and their use to treat diseases or conditions which are caused by overshooting immune reactions and a pathologically increased formation of antibodies, in particular of autoantibodies. Multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis are particularly important fields of application.Type: ApplicationFiled: January 9, 2008Publication date: September 4, 2008Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.Inventors: Robert Huber, Peter Sondermann, Uwe Jacob
-
Publication number: 20080014141Abstract: The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc?RIIb or Fc?IIa.Type: ApplicationFiled: November 26, 2004Publication date: January 17, 2008Inventors: Robert Huber, Peter Sondermann, Uwe Jacob, Kerstin Wendt, Chiara Cabrele, Luis Moroder
-
Publication number: 20070207163Abstract: Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modelling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that can be used to separate and/or enrich antibodies.Type: ApplicationFiled: January 6, 2006Publication date: September 6, 2007Inventors: Peter Sondermann, Robert Ruber, Uwe Jacob
-
Patent number: 7074896Abstract: Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modelling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that can be used to separate and/or enrich antibodies.Type: GrantFiled: December 3, 1999Date of Patent: July 11, 2006Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter Sondermann, Robert Huber, Uwe Jacob
-
Patent number: 7049344Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.Type: GrantFiled: November 22, 2004Date of Patent: May 23, 2006Assignees: Wilex Biotechnology GmbH, Max-Planck-Gessellschaft zur Forderung der Wissenschaften E.V.Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode
-
Publication number: 20050119348Abstract: A method is described for inhibiting urokinase plasminogen activator in a human or animal patient.Type: ApplicationFiled: November 22, 2004Publication date: June 2, 2005Inventors: Viktor Magdolen, Stefan Sperl, Joerg Stuerzebecher, Olaf Wilhelm, Nuria Arroyo De Prada, Luis Moroder, Robert Huber, Uwe Jacob, Wolfram Bode